13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
28 檔
23.9%
In Q2 2024, Sector Gamma As's U.S. equity holdings reached a combined market value of $461.0M, distributed across 28 disclosed stock positions.
In Q2 2024, Sector Gamma As adopted a defensive or profit-taking posture, trimming 22 positions and completely liquidating 2 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including GILD, PFE, BMY) accounted for 23.9% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GILD | Gilead Sciences Inc | Stock-Healthcare | 10.77% | -1.75% | EXIT | |
| 2 | PFE | Pfizer Inc | Stock-Healthcare | 9.36% | -1.99% | -27.77% | |
| 3 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 8.30% | -2.78% | +7.31% | |
| 4 | MDT | Medtronic plc | Stock-Healthcare | 7.79% | +0.24% | -35.69% | |
| 5 | ELV | Elevance Health Inc | Stock-Healthcare | 4.91% | +0.69% | -29.21% | |
| 6 | CVS | Cvs Health CORP | Stock-Healthcare | 4.85% | +1.19% | -28.57% | |
| 7 | INCY | Incyte CORP | Stock-Healthcare | 4.61% | -0.26% | -23.22% | |
| 8 | CAH | Cardinal Health Inc | Stock-Healthcare | 3.93% | -0.64% | -41.34% | |
| 9 | BIIB | Biogen Inc | Stock-Healthcare | 3.81% | -1.36% | -26.32% | |
| 10 | AMGN | Amgen Inc | Stock-Healthcare | 3.50% | -1.86% | — | |
| 11 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 3.45% | -0.67% | -29.77% | |
| 12 | BAX | Baxter International Inc | Stock-Healthcare | 3.25% | — | -19.53% | |
| 13 | GEHC | GE Healthcare Technology | Stock-Healthcare | 3.03% | +0.77% | -15.54% | |
| 14 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.03% | +0.26% | -3.14% | |
| 15 | BRKR | Bruker CORP | Stock-Healthcare | 2.75% | -0.18% | +2.39% | |
| 16 | ABT | Abbott Laboratories | Stock-Healthcare | 2.72% | +0.78% | — | |
| 17 | THC | Tenet Healthcare CORP | Stock-Healthcare | 2.63% | — | -31.82% | |
| 18 | UHS | Universal Health Services-b | Stock-Healthcare | 2.42% | — | -49.91% | |
| 19 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.39% | +0.05% | -35.29% | |
| 20 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.96% | — | -25.88% | |
| 21 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.95% | +0.46% | -22.19% | |
| 22 | ALKS | Alkermes plc | Stock-Healthcare | 1.75% | — | -23.11% | |
| 23 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.72% | +0.56% | -50.01% | |
| 24 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.38% | — | -44.75% | |
| 25 | QGEN | Qiagen N.V. | Stock-Healthcare | 1.28% | — | -19.24% | |
| 26 | CNC | Centene CORP | Stock-Healthcare | 1.11% | +1.00% | +102.56% | |
| 27 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.95% | -1.67% | EXIT | |
| 28 | VTRS | Viatris Inc | Stock-Healthcare | 0.41% | — | -75.31% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GILD | Gilead Sciences Inc | +5.3% | +58.18% | Add |
| 2 | AMGN | Amgen Inc | +3.5% | NEW | New buy |
| 3 | ABT | Abbott Laboratories | +2.7% | NEW | New buy |
| 4 | IONS | Ionis Pharmaceuticals Inc | +0.9% | -3.14% | Trim |
| 5 | BMY | Bristol-myers Squibb Co | +0.7% | +7.31% | Add |
| 6 | CNC | Centene CORP | +0.6% | +102.56% | Add |
| 7 | AGIO | Agios Pharmaceuticals Inc | +0.6% | -25.88% | Trim |
| 8 | INCY | Incyte CORP | +0.4% | -23.22% | Trim |
| 9 | THC | Tenet Healthcare CORP | +0.3% | -31.82% | Trim |
| 10 | ALNY | Alnylam Pharmaceuticals Inc | +0.2% | -44.75% | Trim |
| 11 | BIIB | Biogen Inc | +0.2% | -26.32% | Trim |
| 12 | QGEN | Qiagen N.V. | 0% | -19.24% | Trim |
| 13 | LNTH | Lantheus Holdings Inc | 0% | -40.23% | Trim |
| 14 | BMRN | Biomarin Pharmaceutical Inc | -0.1% | -22.19% | Trim |
| 15 | ELV | Elevance Health Inc | -0.1% | -29.21% | Trim |
| 16 | GEHC | GE Healthcare Technology | -0.1% | -15.54% | Trim |
| 17 | ALKS | Alkermes plc | -0.2% | -23.11% | Trim |
| 18 | BRKR | Bruker CORP | -0.2% | +2.39% | Add |
| 19 | PFE | Pfizer Inc | -0.3% | -27.77% | Trim |
| 20 | EW | Edwards Lifesciences CORP | -0.5% | -35.29% | Trim |
| 21 | BAX | Baxter International Inc | -0.6% | -19.53% | Trim |
| 22 | ILMN | Illumina Inc | -0.7% | EXIT | Sold out |
| 23 | VTRS | Viatris Inc | -1% | -75.31% | Trim |
| 24 | ZBH | Zimmer Biomet Holdings Inc | -1.1% | -29.77% | Trim |
| 25 | UHS | Universal Health Services-b | -1.2% | -49.91% | Trim |
| 26 | BIO | Bio-rad Laboratories-a | -1.6% | -50.01% | Trim |
| 27 | GMED | Globus Medical Inc - A | -1.6% | EXIT | Sold out |
| 28 | CAH | Cardinal Health Inc | -1.8% | -41.34% | Trim |
| 29 | CVS | Cvs Health CORP | -2.1% | -28.57% | Trim |
| 30 | MDT | Medtronic plc | -2.3% | -35.69% | Trim |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 28 disclosed positions in Q2 2024.
During Q2 2024, Sector Gamma As's top holdings by market value included GILD (10.8%)、PFE (9.4%)、BMY (8.3%). The largest single position, GILD, represented 10.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
AMGN
市值: $9.4M
Top Position Liquidated / Trimmed
GMED
前期市值: $5.7M
In Q2 2024, Sector Gamma As made 30 total portfolio adjustments, initiating 2 new buys, adding to 4 positions, trimming 22 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.